Surmodics, Inc.Surmodics, Inc.Surmodics, Inc.

Surmodics, Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪563.44 M‬USD
−0.81USD
‪−11.54 M‬USD
‪126.08 M‬USD
‪13.71 M‬
Beta (1Y)
0.46
Employees (FY)
389
Change (1Y)
+13 +3.46%
Revenue / Employee (1Y)
‪324.11 K‬USD
Net income / Employee (1Y)
‪−29.67 K‬USD

About Surmodics, Inc.


CEO
Gary R. Maharaj
Headquarters
Eden Prairie
Founded
1979
FIGI
BBG000BZ2QG2
Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. The firm operates through the following segments: Medical Device, In Vitro Diagnostics, and Corporate. The Medical Device segment designs, develops, and manufactures vascular interventional medical devices, surface modification coating technologies, as well as drug-delivery coating technologies. The In Vitro Diagnostics segment is composed of component products and technologies for diagnostic test kits and biomedical research applications. The company was founded in June 1979 and is headquartered in Eden Prairie, MN.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of SRDX is 39.33 USD — it has increased by 0.36% in the past 24 hours. Watch Surmodics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Surmodics, Inc. stocks are traded under the ticker SRDX.
SRDX stock has risen by 2.88% compared to the previous week, the month change is a 2.99% rise, over the last year Surmodics, Inc. has showed a 15.44% increase.
We've gathered analysts' opinions on Surmodics, Inc. future price: according to them, SRDX price has a max estimate of 43.00 USD and a min estimate of 43.00 USD. Watch SRDX chart and read a more detailed Surmodics, Inc. stock forecast: see what analysts think of Surmodics, Inc. and suggest that you do with its stocks.
SRDX reached its all-time high on Sep 4, 2018 with the price of 82.35 USD, and its all-time low was 2.50 USD and was reached on Oct 5, 1998. View more price dynamics on SRDX chart.
See other stocks reaching their highest and lowest prices.
SRDX stock is 1.23% volatile and has beta coefficient of 0.46. Track Surmodics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Surmodics, Inc. there?
Today Surmodics, Inc. has the market capitalization of ‪563.44 M‬, it has increased by 1.21% over the last week.
Yes, you can track Surmodics, Inc. financials in yearly and quarterly reports right on TradingView.
Surmodics, Inc. is going to release the next earnings report on Jan 30, 2025. Keep track of upcoming events with our Earnings Calendar.
SRDX earnings for the last quarter are −0.13 USD per share, whereas the estimation was −0.29 USD resulting in a 55.68% surprise. The estimated earnings for the next quarter are −0.12 USD per share. See more details about Surmodics, Inc. earnings.
Surmodics, Inc. revenue for the last quarter amounts to ‪33.23 M‬ USD, despite the estimated figure of ‪30.40 M‬ USD. In the next quarter, revenue is expected to reach ‪33.37 M‬ USD.
SRDX net income for the last quarter is ‪−3.45 M‬ USD, while the quarter before that showed ‪−7.55 M‬ USD of net income which accounts for 54.34% change. Track more Surmodics, Inc. financial stats to get the full picture.
No, SRDX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 24, 2024, the company has 389.00 employees. See our rating of the largest employees — is Surmodics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Surmodics, Inc. EBITDA is ‪6.99 M‬ USD, and current EBITDA margin is 5.35%. See more stats in Surmodics, Inc. financial statements.
Like other stocks, SRDX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Surmodics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Surmodics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Surmodics, Inc. stock shows the buy signal. See more of Surmodics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.